Reverse split will consolidate Femasys (NASDAQ: FEMY) common shares 20-to-1

Rhea-AI Filing Summary

Femasys Inc. will implement a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026. Each 20 pre-split shares will be combined into one share, and no cash will be paid for fractional shares, which will be rounded up to the next whole share at the DTC participant level.

The split-adjusted shares will begin trading on June 8, 2026 under the same ticker symbol “FEMY,” but with a new CUSIP number, 31447E 204. Stockholders of record will receive updated account details from the company’s transfer agent, Broadridge Investor Communication Solutions, Inc.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Reverse split ratio: 1-for-20 Effective time: 4:30 p.m. Eastern Time Split-adjusted trading date: June 8, 2026 +2 more

5 metrics

Reverse split ratio 1-for-20 Each 20 pre-split common shares combined into one share

Effective time 4:30 p.m. Eastern Time Reverse split effective on June 5, 2026

Split-adjusted trading date June 8, 2026 Common stock begins trading on a split-adjusted basis

New CUSIP 31447E 204 CUSIP for common stock after reverse split

Rounding treatment Fractional shares rounded up Rounding to next whole share at DTC participant level

Key Terms

reverse stock split, CUSIP, emerging growth company, forward-looking statements, +1 more

5 terms

reverse stock split financial

"it will effect a 1-for-20 reverse stock split of its common stock"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

CUSIP financial

"The new CUSIP number for the Common Stock following the reverse stock split is 31447E 204"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

emerging growth company regulatory

"Emerging growth company On June 4, 2026, Femasys Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

forward-looking statements regulatory

"Forward-Looking Statements This on contains forward-looking statements that are subject to substantial risks"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

total addressable market financial

"estimates regarding the total addressable market for our products and product candidate"

Total addressable market is the total potential sales opportunity for a product or service if it were to reach every possible customer. It helps investors understand the maximum size of the market and the growth potential for a business. Think of it as the entire pie available to be shared, indicating how big the opportunity could be.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false000133900500013390052026-06-042026-06-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2026

Femasys Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-40492	11-3713499
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100 Suwanee, Georgia		30024
(Address of principal executive offices)		(Zip Code)

(770) 500-3910

(Registrant’s telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		FEMY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

On June 4, 2026, Femasys Inc. (the “Company”) announced that it will effect a 1-for-20 reverse stock split of its common stock, par value $0.001 per share (the “Common Stock”), that will become effective at 4:30 p.m. Eastern Time on June 5, 2026. The Common Stock will begin trading on a split-adjusted basis with the open of the market on June 8, 2026. The Common Stock will continue to trade under the existing trading symbol “FEMY.” The new CUSIP number for the Common Stock following the reverse stock split is 31447E 204.

As a result of the reverse stock split, each 20 pre-split shares of Common Stock outstanding will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares of Common Stock will be issued in connection with the reverse stock split. Instead, fractional shares will be rounded up to the next whole share at the Depository Trust Company (DTC) participant level.

Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Broadridge Investor Communication Solutions, Inc. Broadridge can be reached at (844) 998-0339 or by email at shareholder@broadridge.com.

The information furnished in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; our ability to develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the Securities and Exchange Commission. Forward-looking statements contained in this Current Report on Form 8-K are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Femasys Inc.
	By:	/s/ Kathy Lee-Sepsick
	Name: Kathy Lee-Sepsick
	Title: Chief Executive Officer
Date: June 4, 2026

FAQ

What did Femasys Inc. (FEMY) announce in this 8-K?

Femasys Inc. announced a 1-for-20 reverse stock split of its common stock. This consolidates every 20 existing shares into one share, changing the share count but not the company’s overall value. The move is a structural change to the stock, not an operational update.

When does the Femasys (FEMY) reverse stock split take effect?

The reverse stock split becomes effective at 4:30 p.m. Eastern Time on June 5, 2026. Shares will then begin trading on a split-adjusted basis when the market opens on June 8, 2026, meaning prices and share counts will reflect the new 1-for-20 ratio.

How will the 1-for-20 reverse stock split affect FEMY shareholders?

Every holder of Femasys common stock will have 20 pre-split shares combined into one post-split share. The economic stake remains the same in aggregate. Instead of issuing fractional shares, positions will be rounded up to the next whole share at the DTC participant level.

Will Femasys (FEMY) change its trading symbol after the reverse split?

Femasys common stock will continue trading under the symbol “FEMY” after the reverse split. The only identifier changing is the CUSIP number, which will become 31447E 204. Trading will reflect the split-adjusted share count starting June 8, 2026.

What is the new CUSIP for Femasys (FEMY) after the reverse split?

Following the reverse stock split, Femasys common stock will have a new CUSIP number: 31447E 204. The CUSIP change helps market participants and brokers distinguish post-split shares from pre-split shares while the ticker symbol FEMY remains unchanged.

How will fractional Femasys (FEMY) shares be handled in the reverse split?

Femasys will not issue fractional shares in the reverse split. Instead, any fractional position resulting from the 1-for-20 consolidation will be rounded up to the next whole share at the Depository Trust Company (DTC) participant level, simplifying shareholder positions.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 22.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 16.2 KB